Morfea Ampollosa tratamiento exitoso con fototerapia UVA 1, calcipotriol y superóxido dismutasa tópico, reporte de un caso
Resumen
La morfea ampollosa es un tipo infrecuente de morfea, por esta razón existe poca evidencia en la literatura acerca del mejor tratamiento para esta patología. Presentamos el caso de una niña de 10 años a quien se le realizó un diagnóstico de morfea ampollosa, y fue tratada exitosamente con fototerapia UVA-1, calcipotriol y superóxido dismutasa.Descargas
Referencias bibliográficas
Fett and Werth. Update on morphea, Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. February 2011;64:217-28.
Marsol B. Update on the Classification and Treatment of Localized Scleroderma. Actas Dermosifiliogr. 2013;104(8):654-666.
Yasar S, Mumcuoglu C, Serdar Z, Gunes P. Case of Lichen Sclerosus et Atrophicus Accompanying Bullous Morphea. Ann Dermatol. 2011; Vol. 23, Suppl. 3: S354-S355.http://dx.doi.org/10.5021/ad.2011.23.S3.S354
Zwischenberger and Jacobe. A systematic review of morphea treatments and therapeutic algorithm, J Am Acad Dermatol, Nov 2011; volume 65, number 5.
Jia H, Chen X, Chi J, Zhao C, Cao Y, Zeng X, Chen X, Nanjing. A case of Bullous morphea reported in mainland China, International Journal of Dermatology. 2002; 41, 948-950.http://dx.doi.org/10.1046/j.1365-4362.2002.16672.x
Martin L, Kirsner R. Ulcers caused by bullous morphea treated with tissue-engineered skin. Dermatologic surgery. International Journal of Dermatology. 2003; 42, 402–404.http://dx.doi.org/10.1046/j.1365-4362.2003.01763.x
Fiala K, Wells M, Mullinax K, Stetson C, Paulger B. Linear Morphea Presenting as Acquired Unilateral Edema. Pediatric Dermatology. 2007; Vol. 24 No. 2 147–150.http://dx.doi.org/10.1111/j.1525-1470.2007.00363.x
Kavala M, Zindanci I, Demirkesen C, Beyhan E, Torkoglu Z. Intertriginous bullous morphea: A clue for the pathogenesis. Indian J Dermatol Venereol Leprol. July August 2007; Vol 73, Issue 4.
Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T, A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized Scleroderma, J Am Acad Dermatol. March 2006; volume 54, number 3.http://dx.doi.org/10.1016/j.jaad.2005.11.1063
Gambichler T, Terras S, Kreuter A, Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: Facts and controversies. Clinics in Dermatology. 2013; 31, 438–454.http://dx.doi.org/10.1016/j.clindermatol.2013.01.011
Sator P, Radakovic S, Schulmeister K, Hönigsmann H, Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol. May 2009;Volume 60;number 5;786-791.http://dx.doi.org/10.1016/j.jaad.2008.12.013
Kroft E, Berkhof N, Van de Kerkhof P, Gerritsen R, Jong E, Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. J Am Acad Dermatol 2008; volume 59, number 6, 1017-1030.http://dx.doi.org/10.1016/j.jaad.2008.07.042
Cunningham B, Landells I, Langman C, Sailer D, Paller A. Topical calcipotriene for morphea/linear scleroderma. Journal of the American Academy of Dermatology. August 1998;39:211-5.http://dx.doi.org/10.1016/S0190-9622(98)70077-5
Jablonska S, Blaszczyk M, Scleroderma and Sclerotic Skin Conditions: Unapproved Treatments. Clinics in Dermatology Y 2002;20:634–637.http://dx.doi.org/10.1016/S0738-081X(02)00283-3
Shahriari M, Kerr P, Slade K, Grant-Kels J. Vitamin D and the skin. Clinics in Dermatology. 2010; 28: 663–668.http://dx.doi.org/10.1016/j.clindermatol.2010.03.030
Parish J, Topical Vitamin D3 Analogues: Unapproved Uses, Dosages, or Indications. Clinics in Dermatology Y 2002;20:558–562.http://dx.doi.org/10.1016/S0738-081X(02)00269-9
Nagai M, Hasegawa M, Takehara K, Sato S. Novel Autoantibody to Cu/Zn Superoxide Dismutase in Patients with Localized Scleroderma. J Invest Dermatol. 2004:122:594 –601.http://dx.doi.org/10.1111/j.0022-202X.2004.22333.x
Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K. Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Exp Dermatol. 2004: 13: 357–360.http://dx.doi.org/10.1111/j.0906-6705.2004.00160.x
Treiber N, Peters T, Sindrilaru A, Huber R, Kohn M, Menke A, Briviba K, Kreppel F, Basu A, Maity P, Koller M, Iben S, Wlaschek M, Kochanek S, Scharffetter-Kochane K. Overexpression of manganese superoxide dismutase in human dermal fibroblasts enhances the contraction of free floating collagen lattice: implications for ageing and hyperplastic scar formation. Arch Dermatol Res. 2009: 301:273–287.http://dx.doi.org/10.1007/s00403-009-0935-9
Storz and Imlay. Oxidative stress. Current Opinion in Microbiology 1999, 2:188-l 94.
.png)
